Showing results (201-210 of 456) with videos related to

Sort By:
Pageof 46
Cancer|December 15, 1991
Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumorsA D Seidman, H I Scher, M H Heinemann, et al.
European Urology|October 4, 2020
Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer MonitoringFred Saad, Cora N Sternberg, Eleni Efstathiou, et al.
European Journal of Cancer (Oxford, England : 1990)|December 4, 2010
The requirements of a specialist Prostate Cancer Unit: a discussion paper from the European School of OncologyRiccardo Valdagni, Peter Albers, Chris Bangma, et al.
European Journal of Cancer (Oxford, England : 1990)|June 22, 2011
Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trialD Cella, A S Pickard, M S Duh, et al.
European Urology Oncology|July 6, 2019
Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical TrialAndrew J Armstrong, Ping Lin, Celestia S Higano, et al.
Prostate Cancer and Prostatic Diseases|May 15, 2020
Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancerNeal Shore, Celestia S Higano, Daniel J George, et al.
The New England Journal of Medicine|June 28, 2018
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate CancerMaha Hussain, Karim Fizazi, Fred Saad, et al.
The Oncologist|June 17, 2024
TRIUMPH: phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline homologous recombination repair gene mutationsMark C Markowski, Cora N Sternberg, Hao Wang, et al.
European Urology|April 21, 2018
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision OncologyPhilipp Nuhn, Johann S De Bono, Karim Fizazi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 20, 2009
Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancerC N Sternberg, H Dumez, H Van Poppel, et al.
Pageof 46